Insider Selling: Intuitive Surgical, Inc. (NASDAQ:ISRG) CFO Sells 188 Shares of Stock

Intuitive Surgical, Inc. (NASDAQ:ISRG) CFO Jamie Samath sold 188 shares of the company’s stock in a transaction on Friday, February 28th. The stock was sold at an average price of $566.94, for a total transaction of $106,584.72. Following the sale, the chief financial officer now directly owns 7,162 shares of the company’s stock, valued at approximately $4,060,424.28. This represents a 2.56 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Jamie Samath also recently made the following trade(s):

• On Monday, February 10th, Jamie Samath sold 269 shares of Intuitive Surgical stock. The stock was sold at an average price of $590.00, for a total transaction of $158,710.00.
• On Wednesday, January 29th, Jamie Samath sold 94 shares of Intuitive Surgical stock. The shares were sold at an average price of $571.11, for a total value of $53,684.34.
• On Tuesday, December 10th, Jamie Samath sold 270 shares of Intuitive Surgical stock. The stock was sold at an average price of $540.15, for a total value of $145,840.50.

Intuitive Surgical Stock Performance

ISRG traded down $6.17 during midday trading on Monday, reaching $566.98. 1,705,279 shares of the company were exchanged, compared to its average volume of 1,732,928. The stock has a market capitalization of $201.95 billion, a P/E ratio of 88.45, a PEG ratio of 5.85 and a beta of 1.39. The stock’s 50-day simple moving average is $570.66 and its 200 day simple moving average is $530.08. Intuitive Surgical, Inc. has a one year low of $364.17 and a one year high of $616.00.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. Piper Sandler reaffirmed an “overweight” rating and issued a $670.00 price target (up from $538.00) on shares of Intuitive Surgical in a research report on Friday, January 24th. Royal Bank of Canada boosted their target price on shares of Intuitive Surgical from $611.00 to $641.00 in a research report on Monday, January 27th. Truist Financial increased their price target on shares of Intuitive Surgical from $640.00 to $666.00 and gave the company a “buy” rating in a report on Friday, January 24th. Evercore ISI boosted their price objective on shares of Intuitive Surgical from $490.00 to $530.00 in a report on Monday, January 27th. Finally, Stifel Nicolaus increased their target price on shares of Intuitive Surgical from $525.00 to $610.00 and gave the company a “buy” rating in a research note on Thursday, December 5th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $613.10.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Atala Financial Inc bought a new position in shares of Intuitive Surgical during the fourth quarter worth $25,000. Berbice Capital Management LLC acquired a new stake in Intuitive Surgical during the 4th quarter worth $26,000. Parvin Asset Management LLC bought a new position in Intuitive Surgical during the fourth quarter worth about $26,000. BankPlus Trust Department acquired a new position in Intuitive Surgical in the fourth quarter valued at about $28,000. Finally, Hurley Capital LLC bought a new stake in shares of Intuitive Surgical in the fourth quarter worth about $28,000. Institutional investors and hedge funds own 83.64% of the company’s stock.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.